Innovative Anti-Tumor Drug

Innovative Anti-Tumor Drug, LX-039, Shows Promise in Phase I Clinical Study Data Presented at ESMO 2023

SHANGHAI, Oct. 23, 2023 — Luoxin Pharmaceutical Group Stock Co., Ltd. (Luoxin Pharmaceutical) has made a significant stride in the…